Pupils can be pharmacologically dilated after death, study finds

Article

 

Seattle-Meaningful pharmacological dilation of pupils is possible after death, according to results from a new study conducted at the University of South Florida.

Fourteen eyes were obtained by the Lions Eye Institute for Transplant & Research (LEITR) between December 2012 and April 2013. LEITR inspected the eyes for iris color and signs of abnormalities and reviewed pre-death patient histories. None of the eyes were excluded due to a prior history of iris surgery, iris trauma, iris melanoma, iritis, or iridoschisis.

At study onset, images of the pupils were recorded on a digital camera, and then two drops of a solution of 10% phenylephrine and 1% tropicamide were placed on the surface of the corneas. Seven of the eyes received drops pre-procurement and seven post-procurement. The set of drops was repeated twice, every 3 minutes. Pupils were then measured at 20 minutes and at 60 minutes with a millimeter ruler and recorded on a digital camera for future analysis.

The findings showed that effective pupillary dilation was achieved up to 24 hours after death. Pupil dilation from 0.7mm to 2.6mm was measured and seen across a range of iris colors both pre- and post- tissue procurement.ODT

Recent Videos
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
A. Paul Chous, MA, OD, FAAO, details a presentation on this year's updates on diabetes given at this year's Academy meeting
Sherrol Reynolds, OD, FAAO, said that multimodel imaging has been a game changer in assessing the choroidal function and structural changes in various disease conditions.
Susan Gromacki, OD, FAAO, FSLS, provides key takeaways from this year's American Academy of Optometry symposium genetics and the cornea.
Roya Attar gives an overview of her presentation, "Decoding the Retina: The Value of Genetic Testing In Inherited Disorders," presented with Mohammad Rafieetary, OD, FAAO, FORS, ABO, ABCMO.
Ian Ben Gaddie, OD, FAAO, outlines key findings from a recent study evaluating lotilaner in patients with Demodex blepharitis and meibomian gland dysfunction.
© 2024 MJH Life Sciences

All rights reserved.